---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-23-000045"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:46:03.105288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024

## Summary
- Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.
- Cash, equivalents and investments $302.0M as of March 31, 2023; runway expected into 2025.
- Platform (instruments, reagents, software) launch planned for mid-2024.
- Granted 4 new US patents in Q1, raising total to 12 granted patents.
- Announced three winners of First Access Challenge for Early Access Program.

## SEC filing metadata
- accession: 0001808805-23-000045
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/0001808805-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/naut-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-23-000045
- JSON: https://secwatch.observer/filing/0001808805-23-000045.json
- Plain text: https://secwatch.observer/filing/0001808805-23-000045.txt

## Key facts
- Earnings Releases
  Nautilus Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $15.0 million.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss was $15.0 million
  - Result: reported results
  source text: Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/0001808805-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.